Skip to main content
Top
Published in: Brain Tumor Pathology 3/2016

01-07-2016 | Original Article

Activation of multiple angiogenic signaling pathways in hemangiopericytoma

Authors: Daniela Pierscianek, Anna Michel, Nicolai El Hindy, Kathy Keyvani, Philipp Dammann, Neriman Oezkan, Oliver Mueller, Ulrich Sure, Yuan Zhu

Published in: Brain Tumor Pathology | Issue 3/2016

Login to get access

Abstract

Hemangiopericytoma (HPC) is a highly vascularized mesenchymal tumor. Local recurrence and distant metastasis are common features of HPC. Considering the remarkable hyper-vasculature phenotype of HPC, we assumed that dysregulated angiogenic signaling pathways were involved in HPC. The key components of angiogenic signaling pathways including VEGF–VEGF-R2, EphrinB2-EphB4 and DLL4-Notch were examined by real-time RT-PCR, Western blotting and immunostaining in 17 surgical specimens of HPC patients and in 6 controls. A significant upregulation of VEGF and VEGF-R2 associated with elevated levels of p-Akt and proliferating cell nuclear antigen (PCNA) was detected in HPC. Moreover, a dramatic increase in the mRNA and protein expression of EphB4 and its downstream factor p-Erk1/2 was found in HPC. A massive activation of core-components of DLL4-Notch signaling was detected in HPC. Double-immunofluorescent staining confirmed the expression of these upregulated key factors in the endothelial cells of tumor vessels. The present study identified the activation of multiple and crucial angiogenic signaling pathways, which could function individually and/or synergistically to stimulate angiogenesis in HPC and eventually contribute to tumor growth and progression. Our findings emphasize the importance to target multiple angiogenic signaling pathways when an anti-angiogenic therapy is considered for this highly vascularized tumor.
Appendix
Available only for authorised users
Literature
1.
go back to reference Bolos V, Grego-Bessa J, de la Pompa JL (2007) Notch signaling in development and cancer. Endocr Rev 28:339–363CrossRefPubMed Bolos V, Grego-Bessa J, de la Pompa JL (2007) Notch signaling in development and cancer. Endocr Rev 28:339–363CrossRefPubMed
2.
go back to reference Diehl S, Bruno R, Wilkinson GA, Loose DA, Wilting J, Schweigerer L, Klein R (2005) Altered expression patterns of EphrinB2 and EphB2 in human umbilical vessels and congenital venous malformations. Pediatr Res 57:537–544CrossRefPubMed Diehl S, Bruno R, Wilkinson GA, Loose DA, Wilting J, Schweigerer L, Klein R (2005) Altered expression patterns of EphrinB2 and EphB2 in human umbilical vessels and congenital venous malformations. Pediatr Res 57:537–544CrossRefPubMed
3.
go back to reference Dopeso H, Mateo-Lozano S, Mazzolini R, Rodrigues P, Lagares-Tena L, Ceron J, Romero J, Esteves M, Landolfi S, Hernandez-Losa J, Castano J, Wilson AJ, Ramon y Cajal S, Mariadason JM, Schwartz S, Jr., Arango D (2009) The receptor tyrosine kinase EPHB4 has tumor suppressor activities in intestinal tumorigenesis. Cancer Research 69:7430–7438 Dopeso H, Mateo-Lozano S, Mazzolini R, Rodrigues P, Lagares-Tena L, Ceron J, Romero J, Esteves M, Landolfi S, Hernandez-Losa J, Castano J, Wilson AJ, Ramon y Cajal S, Mariadason JM, Schwartz S, Jr., Arango D (2009) The receptor tyrosine kinase EPHB4 has tumor suppressor activities in intestinal tumorigenesis. Cancer Research 69:7430–7438
4.
go back to reference Dvorak HF (2002) Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy. J Clin Oncol 20:4368–4380CrossRefPubMed Dvorak HF (2002) Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy. J Clin Oncol 20:4368–4380CrossRefPubMed
5.
go back to reference El Hindy N, Keyvani K, Pagenstecher A, Dammann P, Sandalcioglu IE, Sure U, Zhu Y (2013) Implications of Dll4-Notch signaling activation in primary glioblastoma multiforme. Neuro Oncol 15:1366–1378CrossRefPubMedPubMedCentral El Hindy N, Keyvani K, Pagenstecher A, Dammann P, Sandalcioglu IE, Sure U, Zhu Y (2013) Implications of Dll4-Notch signaling activation in primary glioblastoma multiforme. Neuro Oncol 15:1366–1378CrossRefPubMedPubMedCentral
6.
go back to reference Flaherty KT, Manola JB, Pins M, McDermott DF, Atkins MB, Dutcher JJ, George DJ, Margolin KA, DiPaola RS (2015) BEST: a randomized phase II study of vascular endothelial growth factor, RAF kinase, and mammalian target of rapamycin combination targeted therapy with bevacizumab, sorafenib, and temsirolimus in advanced renal cell carcinoma—a trial of the ECOG-ACRIN cancer research group (E2804). J Clin Oncol 33:2384–2391CrossRefPubMed Flaherty KT, Manola JB, Pins M, McDermott DF, Atkins MB, Dutcher JJ, George DJ, Margolin KA, DiPaola RS (2015) BEST: a randomized phase II study of vascular endothelial growth factor, RAF kinase, and mammalian target of rapamycin combination targeted therapy with bevacizumab, sorafenib, and temsirolimus in advanced renal cell carcinoma—a trial of the ECOG-ACRIN cancer research group (E2804). J Clin Oncol 33:2384–2391CrossRefPubMed
7.
8.
9.
go back to reference Franceschi E, Brandes AA (2015) The role of bevacizumab in recurrent glioblastoma: new insights from randomized trials. CNS Oncol 4:117–119CrossRefPubMed Franceschi E, Brandes AA (2015) The role of bevacizumab in recurrent glioblastoma: new insights from randomized trials. CNS Oncol 4:117–119CrossRefPubMed
10.
go back to reference Guthrie BL, Ebersold MJ, Scheithauer BW, Shaw EG (1989) Meningeal hemangiopericytoma: histopathological features, treatment, and long-term follow-up of 44 cases. Neurosurgery 25:514–522CrossRefPubMed Guthrie BL, Ebersold MJ, Scheithauer BW, Shaw EG (1989) Meningeal hemangiopericytoma: histopathological features, treatment, and long-term follow-up of 44 cases. Neurosurgery 25:514–522CrossRefPubMed
11.
go back to reference Hammes LS, Tekmal RR, Naud P, Edelweiss MI, Kirma N, Valente PT, Syrjanen KJ, Cunha-Filho JS (2008) Up-regulation of VEGF, c-fms and COX-2 expression correlates with severity of cervical cancer precursor (CIN) lesions and invasive disease. Gynecol Oncol 110:445–451CrossRefPubMed Hammes LS, Tekmal RR, Naud P, Edelweiss MI, Kirma N, Valente PT, Syrjanen KJ, Cunha-Filho JS (2008) Up-regulation of VEGF, c-fms and COX-2 expression correlates with severity of cervical cancer precursor (CIN) lesions and invasive disease. Gynecol Oncol 110:445–451CrossRefPubMed
12.
go back to reference Hassan-Mohamed I, Giorgio C, Incerti M, Russo S, Pala D, Pasquale EB, Zanotti I, Vicini P, Barocelli E, Rivara S, Mor M, Lodola A, Tognolini M (2014) UniPR129 is a competitive small molecule Eph-ephrin antagonist blocking in vitro angiogenesis at low micromolar concentrations. Br J Pharmacol 171:5195–5208CrossRefPubMedPubMedCentral Hassan-Mohamed I, Giorgio C, Incerti M, Russo S, Pala D, Pasquale EB, Zanotti I, Vicini P, Barocelli E, Rivara S, Mor M, Lodola A, Tognolini M (2014) UniPR129 is a competitive small molecule Eph-ephrin antagonist blocking in vitro angiogenesis at low micromolar concentrations. Br J Pharmacol 171:5195–5208CrossRefPubMedPubMedCentral
13.
14.
go back to reference Jain RK, di Tomaso E, Duda DG, Loeffler JS, Sorensen AG, Batchelor TT (2007) Angiogenesis in brain tumours. Nat Rev Neurosci 8:610–622CrossRefPubMed Jain RK, di Tomaso E, Duda DG, Loeffler JS, Sorensen AG, Batchelor TT (2007) Angiogenesis in brain tumours. Nat Rev Neurosci 8:610–622CrossRefPubMed
15.
go back to reference Jin MM, Ye YZ, Qian ZD, Zhang YB (2015) Notch signaling molecules as prognostic biomarkers for non-small cell lung cancer. Oncol Lett 10:3252–3260PubMedPubMedCentral Jin MM, Ye YZ, Qian ZD, Zhang YB (2015) Notch signaling molecules as prognostic biomarkers for non-small cell lung cancer. Oncol Lett 10:3252–3260PubMedPubMedCentral
16.
go back to reference Kargiotis O, Rao JS, Kyritsis AP (2006) Mechanisms of angiogenesis in gliomas. J Neurooncol 78:281–293CrossRefPubMed Kargiotis O, Rao JS, Kyritsis AP (2006) Mechanisms of angiogenesis in gliomas. J Neurooncol 78:281–293CrossRefPubMed
17.
go back to reference Khansaard W, Techasen A, Namwat N, Yongvanit P, Khuntikeo N, Puapairoj A, Loilome W (2014) Increased EphB2 expression predicts cholangiocarcinoma metastasis. Tumour Biol J Int Soc Oncodev Biol Med 35:10031–10041CrossRef Khansaard W, Techasen A, Namwat N, Yongvanit P, Khuntikeo N, Puapairoj A, Loilome W (2014) Increased EphB2 expression predicts cholangiocarcinoma metastasis. Tumour Biol J Int Soc Oncodev Biol Med 35:10031–10041CrossRef
18.
19.
go back to reference Kumar SR, Scehnet JS, Ley EJ, Singh J, Krasnoperov V, Liu R, Manchanda PK, Ladner RD, Hawes D, Weaver FA, Beart RW, Singh G, Nguyen C, Kahn M, Gill PS (2009) Preferential induction of EphB4 over EphB2 and its implication in colorectal cancer progression. Cancer Res 69:3736–3745CrossRefPubMed Kumar SR, Scehnet JS, Ley EJ, Singh J, Krasnoperov V, Liu R, Manchanda PK, Ladner RD, Hawes D, Weaver FA, Beart RW, Singh G, Nguyen C, Kahn M, Gill PS (2009) Preferential induction of EphB4 over EphB2 and its implication in colorectal cancer progression. Cancer Res 69:3736–3745CrossRefPubMed
20.
go back to reference Li JL, Sainson RC, Shi W, Leek R, Harrington LS, Preusser M, Biswas S, Turley H, Heikamp E, Hainfellner JA, Harris AL (2007) Delta-like 4 Notch ligand regulates tumor angiogenesis, improves tumor vascular function, and promotes tumor growth in vivo. Cancer Res 67:11244–11253CrossRefPubMed Li JL, Sainson RC, Shi W, Leek R, Harrington LS, Preusser M, Biswas S, Turley H, Heikamp E, Hainfellner JA, Harris AL (2007) Delta-like 4 Notch ligand regulates tumor angiogenesis, improves tumor vascular function, and promotes tumor growth in vivo. Cancer Res 67:11244–11253CrossRefPubMed
21.
go back to reference Liersch-Lohn B, Slavova N, Buhr HJ, Bennani-Baiti IM (2016) Differential protein expression and oncogenic gene network link tyrosine kinase ephrin B4 receptor to aggressive gastric and gastroesophageal junction cancers. Int J Cancer 138:1220–1231CrossRefPubMed Liersch-Lohn B, Slavova N, Buhr HJ, Bennani-Baiti IM (2016) Differential protein expression and oncogenic gene network link tyrosine kinase ephrin B4 receptor to aggressive gastric and gastroesophageal junction cancers. Int J Cancer 138:1220–1231CrossRefPubMed
22.
go back to reference Liu W, Ahmad SA, Jung YD, Reinmuth N, Fan F, Bucana CD, Ellis LM (2002) Coexpression of ephrin-Bs and their receptors in colon carcinoma. Cancer 94:934–939CrossRefPubMed Liu W, Ahmad SA, Jung YD, Reinmuth N, Fan F, Bucana CD, Ellis LM (2002) Coexpression of ephrin-Bs and their receptors in colon carcinoma. Cancer 94:934–939CrossRefPubMed
23.
go back to reference Louis DNOH, Wiestler OD, Cavanee WK, Burger PC, Jouvet A, Scheithauer BW, Kleihues P (2007) The 2007 WHO classification of Tumours of the Central Nervous System. Acta Neuropathol 114:97–109CrossRefPubMedPubMedCentral Louis DNOH, Wiestler OD, Cavanee WK, Burger PC, Jouvet A, Scheithauer BW, Kleihues P (2007) The 2007 WHO classification of Tumours of the Central Nervous System. Acta Neuropathol 114:97–109CrossRefPubMedPubMedCentral
24.
go back to reference Maekawa H, Oike Y, Kanda S, Ito Y, Yamada Y, Kurihara H, Nagai R, Suda T (2003) Ephrin-B2 induces migration of endothelial cells through the phosphatidylinositol-3 kinase pathway and promotes angiogenesis in adult vasculature. Arterioscler Thromb Vasc Biol 23:2008–2014CrossRefPubMed Maekawa H, Oike Y, Kanda S, Ito Y, Yamada Y, Kurihara H, Nagai R, Suda T (2003) Ephrin-B2 induces migration of endothelial cells through the phosphatidylinositol-3 kinase pathway and promotes angiogenesis in adult vasculature. Arterioscler Thromb Vasc Biol 23:2008–2014CrossRefPubMed
25.
go back to reference Noguera-Troise I, Daly C, Papadopoulos NJ, Coetzee S, Boland P, Gale NW, Lin HC, Yancopoulos GD, Thurston G (2006) Blockade of Dll4 inhibits tumour growth by promoting non-productive angiogenesis. Nature 444:1032–1037CrossRefPubMed Noguera-Troise I, Daly C, Papadopoulos NJ, Coetzee S, Boland P, Gale NW, Lin HC, Yancopoulos GD, Thurston G (2006) Blockade of Dll4 inhibits tumour growth by promoting non-productive angiogenesis. Nature 444:1032–1037CrossRefPubMed
26.
go back to reference Patel NS, Dobbie MS, Rochester M, Steers G, Poulsom R, Le Monnier K, Cranston DW, Li JL, Harris AL (2006) Up-regulation of endothelial delta-like 4 expression correlates with vessel maturation in bladder cancer. Clin Cancer Res 12:4836–4844CrossRefPubMed Patel NS, Dobbie MS, Rochester M, Steers G, Poulsom R, Le Monnier K, Cranston DW, Li JL, Harris AL (2006) Up-regulation of endothelial delta-like 4 expression correlates with vessel maturation in bladder cancer. Clin Cancer Res 12:4836–4844CrossRefPubMed
27.
go back to reference Piha-Paul SA, Munster PN, Hollebecque A, Argiles G, Dajani O, Cheng JD, Wang R, Swift A, Tosolini A, Gupta S (2015) Results of a phase 1 trial combining ridaforolimus and MK-0752 in patients with advanced solid tumours. Eur J Cancer 51:1865–1873CrossRefPubMed Piha-Paul SA, Munster PN, Hollebecque A, Argiles G, Dajani O, Cheng JD, Wang R, Swift A, Tosolini A, Gupta S (2015) Results of a phase 1 trial combining ridaforolimus and MK-0752 in patients with advanced solid tumours. Eur J Cancer 51:1865–1873CrossRefPubMed
28.
go back to reference Reedijk M, Odorcic S, Chang L, Zhang H, Miller N, McCready DR, Lockwood G, Egan SE (2005) High-level coexpression of JAG1 and NOTCH1 is observed in human breast cancer and is associated with poor overall survival. Cancer Res 65:8530–8537CrossRefPubMed Reedijk M, Odorcic S, Chang L, Zhang H, Miller N, McCready DR, Lockwood G, Egan SE (2005) High-level coexpression of JAG1 and NOTCH1 is observed in human breast cancer and is associated with poor overall survival. Cancer Res 65:8530–8537CrossRefPubMed
29.
go back to reference Sahebjam S, Bedard PL, Castonguay V, Chen Z, Reedijk M, Liu G, Cohen B, Zhang WJ, Clarke B, Zhang T, Kamel-Reid S, Chen H, Ivy SP, Razak AR, Oza AM, Chen EX, Hirte HW, McGarrity A, Wang L, Siu LL, Hotte SJ (2013) A phase I study of the combination of ro4929097 and cediranib in patients with advanced solid tumours (PJC-004/NCI 8503). Br J Cancer 109:943–949CrossRefPubMedPubMedCentral Sahebjam S, Bedard PL, Castonguay V, Chen Z, Reedijk M, Liu G, Cohen B, Zhang WJ, Clarke B, Zhang T, Kamel-Reid S, Chen H, Ivy SP, Razak AR, Oza AM, Chen EX, Hirte HW, McGarrity A, Wang L, Siu LL, Hotte SJ (2013) A phase I study of the combination of ro4929097 and cediranib in patients with advanced solid tumours (PJC-004/NCI 8503). Br J Cancer 109:943–949CrossRefPubMedPubMedCentral
30.
go back to reference Salvucci O, Tosato G (2012) Essential roles of EphB receptors and EphrinB ligands in endothelial cell function and angiogenesis. Adv Cancer Res 114:21–57CrossRefPubMedPubMedCentral Salvucci O, Tosato G (2012) Essential roles of EphB receptors and EphrinB ligands in endothelial cell function and angiogenesis. Adv Cancer Res 114:21–57CrossRefPubMedPubMedCentral
31.
go back to reference Sawamiphak S, Seidel S, Essmann CL, Wilkinson GA, Pitulescu ME, Acker T, Acker-Palmer A (2010) Ephrin-B2 regulates VEGFR2 function in developmental and tumour angiogenesis. Nature 465:487–491CrossRefPubMed Sawamiphak S, Seidel S, Essmann CL, Wilkinson GA, Pitulescu ME, Acker T, Acker-Palmer A (2010) Ephrin-B2 regulates VEGFR2 function in developmental and tumour angiogenesis. Nature 465:487–491CrossRefPubMed
32.
go back to reference Schwartzberg LS, Rivera F, Karthaus M, Fasola G, Canon JL, Hecht JR, Yu H, Oliner KS, Go WY (2014) PEAK: a randomized, multicenter phase II study of panitumumab plus modified fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) or bevacizumab plus mFOLFOX6 in patients with previously untreated, unresectable, wild-type KRAS exon 2 metastatic colorectal cancer. J Clin Oncol 32:2240–2247CrossRefPubMed Schwartzberg LS, Rivera F, Karthaus M, Fasola G, Canon JL, Hecht JR, Yu H, Oliner KS, Go WY (2014) PEAK: a randomized, multicenter phase II study of panitumumab plus modified fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) or bevacizumab plus mFOLFOX6 in patients with previously untreated, unresectable, wild-type KRAS exon 2 metastatic colorectal cancer. J Clin Oncol 32:2240–2247CrossRefPubMed
33.
go back to reference Shutter JR, Scully S, Fan W, Richards WG, Kitajewski J, Deblandre GA, Kintner CR, Stark KL (2000) Dll4, a novel Notch ligand expressed in arterial endothelium. Genes Dev 14:1313–1318PubMedPubMedCentral Shutter JR, Scully S, Fan W, Richards WG, Kitajewski J, Deblandre GA, Kintner CR, Stark KL (2000) Dll4, a novel Notch ligand expressed in arterial endothelium. Genes Dev 14:1313–1318PubMedPubMedCentral
34.
35.
go back to reference Vuorinen V, Sallinen P, Haapasalo H, Visakorpi T, Kallio M, Jaaskelainen J (1996) Outcome of 31 intracranial haemangiopericytomas: poor predictive value of cell proliferation indices. Acta Neurochir (Wien) 138:1399–1408CrossRef Vuorinen V, Sallinen P, Haapasalo H, Visakorpi T, Kallio M, Jaaskelainen J (1996) Outcome of 31 intracranial haemangiopericytomas: poor predictive value of cell proliferation indices. Acta Neurochir (Wien) 138:1399–1408CrossRef
36.
go back to reference Wick W, Platten M, Wick A, Hertenstein A, Radbruch A, Bendszus M, Winkler F (2015) Current status and future directions of anti-angiogenic therapy for gliomas. Neuro Oncol. doi:10.1093/neuonc/nov180 Wick W, Platten M, Wick A, Hertenstein A, Radbruch A, Bendszus M, Winkler F (2015) Current status and future directions of anti-angiogenic therapy for gliomas. Neuro Oncol. doi:10.​1093/​neuonc/​nov180
37.
go back to reference Xu X, Zhao Y, Xu M, Dai Q, Meng W, Yang J, Qin R (2011) Activation of Notch signal pathway is associated with a poorer prognosis in acute myeloid leukemia. Med Oncol 28(Suppl 1):S483–S489CrossRefPubMed Xu X, Zhao Y, Xu M, Dai Q, Meng W, Yang J, Qin R (2011) Activation of Notch signal pathway is associated with a poorer prognosis in acute myeloid leukemia. Med Oncol 28(Suppl 1):S483–S489CrossRefPubMed
38.
go back to reference Yuan X, Zhang M, Wu H, Xu H, Han N, Chu Q, Yu S, Chen Y, Wu K (2015) Expression of Notch1 Correlates with Breast Cancer Progression and Prognosis. PLoS One 10:e0131689CrossRefPubMedPubMedCentral Yuan X, Zhang M, Wu H, Xu H, Han N, Chu Q, Yu S, Chen Y, Wu K (2015) Expression of Notch1 Correlates with Breast Cancer Progression and Prognosis. PLoS One 10:e0131689CrossRefPubMedPubMedCentral
39.
go back to reference Zhang J, Hughes S (2006) Role of the ephrin and Eph receptor tyrosine kinase families in angiogenesis and development of the cardiovascular system. J Pathol 208:453–461CrossRefPubMed Zhang J, Hughes S (2006) Role of the ephrin and Eph receptor tyrosine kinase families in angiogenesis and development of the cardiovascular system. J Pathol 208:453–461CrossRefPubMed
40.
go back to reference Zhang M, Ye G, Li J, Wang Y (2015) Recent advance in molecular angiogenesis in glioblastoma: the challenge and hope for anti-angiogenic therapy. Brain Tumor Pathol 32:229–236CrossRefPubMed Zhang M, Ye G, Li J, Wang Y (2015) Recent advance in molecular angiogenesis in glioblastoma: the challenge and hope for anti-angiogenic therapy. Brain Tumor Pathol 32:229–236CrossRefPubMed
Metadata
Title
Activation of multiple angiogenic signaling pathways in hemangiopericytoma
Authors
Daniela Pierscianek
Anna Michel
Nicolai El Hindy
Kathy Keyvani
Philipp Dammann
Neriman Oezkan
Oliver Mueller
Ulrich Sure
Yuan Zhu
Publication date
01-07-2016
Publisher
Springer Japan
Published in
Brain Tumor Pathology / Issue 3/2016
Print ISSN: 1433-7398
Electronic ISSN: 1861-387X
DOI
https://doi.org/10.1007/s10014-016-0256-6

Other articles of this Issue 3/2016

Brain Tumor Pathology 3/2016 Go to the issue